The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

B7-H3-directed ifinatamab deruxtecan, and raludotatug deruxtecan, which binds to CDH6. For MSD – known as Merck & Co in the US and Canada – the deal bolts on three drug candidates that could ...

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

Merck acquired global co-development and co-commercialization rights to patritumab deruxtecan/MK-1022 and two other ADCs, raludotatug deruxtecan/MK-5909 and ifinatamab deruxtecan/MK-2400 from ...

MSD – known as Merck & Co in the US and Canada – acquired rights to HER3-directed ADC patritumab deruxtecan (HER3-DXd), anti-CDH6 candidate raludotatug deruxtecan (R-DXd) and I-DXd last ...

Daiichi and Merck MRK are co-developing and co-commercializing three ADCs, patritumab deruxtecan/MK-1022, raludotatug ...

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung cancer. The first patients with locally advanced or metastatic nonsquamous non ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Tolebrutinib for treating relapsing multiple sclerosis TS ID 11845 Technology appraisal guidance Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous ...

Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC, ifinatamab deruxtecan (I-DXd), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd), a CDH6 directed ADC, are being jointly developed and ...

TROPION-Lung10 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus rilvegostomig as first-line treatment for advanced or metastatic nonsquamous NSCLC with high PD-L1 ...